Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory BiomarkersAccesswire • 05/23/23
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol DeliveryAccesswire • 05/18/23
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical TrialAccesswire • 05/11/23
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol LevelsAccesswire • 03/02/23
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic AdvisorAccesswire • 01/23/23
Lexaria's DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study ProgramAccesswire • 11/29/22
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine StudyAccesswire • 11/01/22
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields 'Remarkable' ResultsNewsfile Corp • 09/20/22